Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rational in silico design identifies two mutations that restore UT28K SARS-CoV-2 monoclonal antibody activity against Omicron BA.1.
Ozawa T, Ikeda Y, Chen L, Suzuki R, Hoshino A, Noguchi A, Kita S, Anraku Y, Igarashi E, Saga Y, Inasaki N, Taminishi S, Sasaki J, Kirita Y, Fukuhara H, Maenaka K, Hashiguchi T, Fukuhara T, Hirabayashi K, Tani H, Kishi H, Niimi H. Ozawa T, et al. Among authors: niimi h. Structure. 2024 Mar 7;32(3):263-272.e7. doi: 10.1016/j.str.2023.12.013. Epub 2024 Jan 15. Structure. 2024. PMID: 38228146
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants.
Ozawa T, Tani H, Anraku Y, Kita S, Igarashi E, Saga Y, Inasaki N, Kawasuji H, Yamada H, Sasaki SI, Somekawa M, Sasaki J, Hayakawa Y, Yamamoto Y, Morinaga Y, Kurosawa N, Isobe M, Fukuhara H, Maenaka K, Hashiguchi T, Kishi H, Kitajima I, Saito S, Niimi H. Ozawa T, et al. Among authors: niimi h. MAbs. 2022 Jan-Dec;14(1):2072455. doi: 10.1080/19420862.2022.2072455. MAbs. 2022. PMID: 35543180 Free PMC article.
Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5.
Kawasuji H, Morinaga Y, Tani H, Saga Y, Yamada H, Yoshida Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Ueno A, Miyajima Y, Nagaoka K, Ono C, Matsuura Y, Niimi H, Yamamoto Y. Kawasuji H, et al. Among authors: niimi h. Microbiol Spectr. 2023 Mar 22;11(2):e0513122. doi: 10.1128/spectrum.05131-22. Online ahead of print. Microbiol Spectr. 2023. PMID: 36946738 Free PMC article.
High interleukin-6 levels induced by COVID-19 pneumonia correlate with increased circulating follicular helper T cell frequency and strong neutralization antibody response in the acute phase of Omicron breakthrough infection.
Kawasuji H, Morinaga Y, Nagaoka K, Tani H, Yoshida Y, Yamada H, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Niimi H, Yamamoto Y. Kawasuji H, et al. Among authors: niimi h. Front Immunol. 2024 Apr 17;15:1377014. doi: 10.3389/fimmu.2024.1377014. eCollection 2024. Front Immunol. 2024. PMID: 38694512 Free PMC article.
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Kawasuji H, Morinaga Y, Tani H, Yamada H, Yoshida Y, Ezaki M, Koshiyama Y, Takegoshi Y, Kaneda M, Murai Y, Kimoto K, Nagaoka K, Niimi H, Yamamoto Y. Kawasuji H, et al. Among authors: niimi h. Vaccine. 2024 Sep 17;42(22):126029. doi: 10.1016/j.vaccine.2024.05.077. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839519 Free article.
385 results